NASDAQ · Biotechnology

Traws Pharma, Inc. (TRAW) Stock

$0.51 +4.10% NASDAQ: TRAW Healthcare

Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19.

Valuation

MetricValue
Price$0.51
Market Cap$4.64M
P/E Ratio-0.56
P/B Ratio-0.98
P/S Ratio1.49
EPS (TTM)$0.82
52-Week High$3.27
52-Week Low$0.46
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE489.90%
ROA-178.40%
ROCE283.33%
Gross Margin-600.00%
Operating Margin-600.00%
Net Margin300.00%
Debt/Equity0.00
Current Ratio0.73

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$3.0M
Operating Profit$-16.0M$-20.0M$-20.0M$-49.0M$-18.0M
Net Profit$-16.0M$-19.0M$-19.0M$-55.0M$9.0M
EPS$-24.01$-22.68$-22.57$-35.21$0.82
Op Margin-7299.1%-8684.5%-8981.4%-21835.4%-640.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$55.0M$39.0M$23.0M$25.0M$11.0M
Total Liabilities$9.0M$11.0M$12.0M$57.0M$11.0M
Cash$55.0M$39.0M$21.0M$21.0M$4.0M
Borrowings$0$0$0$0$0

Latest News

Traws Pharma Says Updated Toxicology Data Being Developed on Influenza Prophylaxis Program MT Newswires · Jun 22, 2026 Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program GlobeNewswire · Jun 22, 2026 SpaceX initiated, Salesforce upgraded: Wall Street's top analyst calls The Fly · Jun 18, 2026 Top Premarket Decliners MT Newswires · Jun 15, 2026 Traws Pharma Delays Phase 2 Influenza Study After UK Regulatory Review; Shares Down Pre-Bell MT Newswires · Jun 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-19.0M$-16.0M$-18.0M$-30.0M$-18.0M
Investing Cash Flow$0$0$0$-4.0M$-5.0M
Financing Cash Flow$1.0M$0$0$0$-2.0M
Net Cash Flow$36.0M$-16.0M$-18.0M$1.0M$-18.0M
Free Cash Flow$-19.0M$-16.0M$-18.0M$-30.0M$-21.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-0.13
FCF Yield-107.09%
Quick Ratio0.43
Interest Coverage0.00
Return 1Y-55.78%
Return 3Y-97.64%
Return 5Y-99.49%

Ownership

Insiders Held5.38%
Institutions Held43.92%
Institutions Float Held46.42%
Institutional HolderSharesReport Date
Adage Capital Partners GP L.L.C.730,0002026-03-31
Ikarian Capital, LLC678,1422026-03-31
Orbimed Advisors LLC.605,5312026-03-31
Squadron Capital Management LLC511,7142026-03-31
Dauntless Investment Group, LLC 416,9982026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BOLT $3.95 -0.50% -0.26 $7.59M 0.00%
BRTX $0.20 -2.11% -0.33 $1.83M 0.00%
CING $4.52 -2.59% -1.08 $25.34M 0.00%
COCP $0.92 +0.14% -1.46 $12.68M 0.00%
DWTX $1.81 +3.14% 1.42 $3.45M 0.00%

About Traws Pharma, Inc.

Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.

Traws Pharma, Inc. is led by CEO Iain D. Dukes, employs 6 people, headquartered in US, publicly traded since 2013.

Traws Pharma, Inc. (TRAW) stock trades at $0.51 with a market capitalization of $4.64M. The stock is valued at a price-to-earnings (P/E) ratio of -0.56, price-to-book of -0.98, price-to-sales of 1.49. Over the past 52 weeks the stock has ranged between $0.46 and $3.27, and currently trades 84.4% below its 52-week high.

On profitability, Traws Pharma, Inc. generates a return on equity (ROE) of 489.90% — well above the market average, a sign of a high-quality business, return on capital employed of 283.33%, an operating margin of -600.00%, a net profit margin of 300.00%.

Official website: www.trawspharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides